China: Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

China Compliance Update: Life Sciences — Spring 2026

In 2026, Chinese regulators have continued their focus on anti-corruption enforcement in the life sciences industry.

China Healthcare

AP

Arnold & Porter

China Boosts Medical Innovation For Public Health

China will accelerate the development of core medical technologies and innovative drugs targeting common and complex diseases, including cardiovascular conditions...

China Healthcare

AC

AFD China

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China has emerged as a global pharmaceutical innovation powerhouse, leveraging its scientific expertise, AI capabilities, and streamlined regulatory environment to accelerate drug development.

China Healthcare

AO

A&O Shearman

China | Market Exclusivity And Data Exclusivity Included In Drug Administration Law Revisions

Marking a milestone in China's drug regulatory landscape, the 2026 Revisions of China's Drug Administration Law introduce data exclusivity and market exclusivity into the regulatory framework...

China Healthcare

SF

Spruson & Ferguson

USITC Will Investigate State Support And Pricing Practices By Chinese Biotechnology Firms

China Healthcare

BC

Bergeson & Campbell

China Life Sciences: 2025 Year In Review

China Healthcare

AP

Arnold & Porter

China On The Move: Key Takeaways From The 2025 NRDL Negotiations And Adjustment

China Healthcare

GT

Greenberg Traurig, LLP

A Legal Commentary On The Latest Implementing Regulations Of The PRC Drug Administration Law

China Healthcare

FP

Fangda Partners

Navigating China's Health Transformation: Opportunities And Challenges For Multinationals

China Healthcare

AC

Ankura Consulting Group LLC

Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China

China Healthcare

HK

Han Kun Law Offices

China Released Draft Medical Device Law For Comments

China Healthcare

HK

Han Kun Law Offices

China Life Sciences Compliance Update: Insurance Fraud Enforcement Campaign And New Ethical Code For HCPs

China Healthcare

AP

Arnold & Porter

China Life Sciences Compliance Update: Kickback And Third-Party Case Study

China Healthcare

AP

Arnold & Porter

Redefining Beauty: Navigating Chinas Medical Aesthetics Upheaval

China Healthcare

KP

KPMG

关于“PCT国际申请附图”，如何有效避坑？

K

Kangxin

A Brief Analysis Of The Impact Of The New Short Swing Trading Rules On Foreign Investors

China Commercial

LO

Llinks Law Offices

海关法领域2025年政策回顾与2026年展望：出口管制、关税及企业应对

China International

AB

AnJie Broad Law Firm

최고인민법원은 지식재산권과 관련된 악의적 소송에 대응한 대표적 판례 발표

K

Kangxin

Analysis Of China’s Draft Administrative Measures For Digital Virtual Human Information Services

China Technology

AB

AnJie Broad Law Firm

See more

Food and Drugs Law

China Compliance Update: Life Sciences — Spring 2026

In 2026, Chinese regulators have continued their focus on anti-corruption enforcement in the life sciences industry.

China Healthcare

AP

Arnold & Porter

SRS v. Alexion药品许可诉讼案评析——兼论中国创新药企BD合同的风险防控与条款设计

特拉华州衡平法院在SRS诉Alexion案中，就跨境医药BD交易中的里程碑付款争议、商业合理努力义务及预期损失量化作出了详尽裁判。本文深入剖析该案判

China Commercial

JT

Beijing Jincheng Tongda & Neal Law Firm

China Boosts Medical Innovation For Public Health

China will accelerate the development of core medical technologies and innovative drugs targeting common and complex diseases, including cardiovascular conditions...

China Healthcare

AC

AFD China

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China Healthcare

AO

A&O Shearman

ライブ販売の商標侵害に厳罰山東高裁、懲罰的賠償で抑止強化

K

Kangxin

China | Market Exclusivity And Data Exclusivity Included In Drug Administration Law Revisions

China Healthcare

SF

Spruson & Ferguson

Interpretation Of The Revised 'Regulations For The Implementation Of The Drug Administration Law' And Compliance Implications

CT

Chang Tsi & Partners

China Life Sciences: 2025 Year In Review

China Healthcare

AP

Arnold & Porter

The Patent Term Compensation And Protection Scope In The Compensated Period For Drug Invention Patents

AC

AFD China

See more

Life Sciences, Biotechnology & Nanotechnology

China Compliance Update: Life Sciences — Spring 2026

In 2026, Chinese regulators have continued their focus on anti-corruption enforcement in the life sciences industry.

China Healthcare

AP

Arnold & Porter

SRS v. Alexion药品许可诉讼案评析——兼论中国创新药企BD合同的风险防控与条款设计

特拉华州衡平法院在SRS诉Alexion案中，就跨境医药BD交易中的里程碑付款争议、商业合理努力义务及预期损失量化作出了详尽裁判。本文深入剖析该案判

China Commercial

JT

Beijing Jincheng Tongda & Neal Law Firm

Judicial Assessment Of Usage Limitations' Impact On The Novelty Of Product Claims

The SPC pointed out in an administrative appeal that, for product claims containing a subject name with usage limitation, the usage limitation must be considered when determining the scope of protection.

AC

AFD China

外資の研究開発投資が拡大　中国、世界のイノベーション拠点

China Government

K

Kangxin

A Stratification Too Far? How The CNIPA Draws The Line On Patient Subgroups In A Recent Precision Medicine Invalidation Case

EI

Eagle IP

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China Healthcare

AO

A&O Shearman

ライブ販売の商標侵害に厳罰山東高裁、懲罰的賠償で抑止強化

K

Kangxin

世界初の「動画MRI」実用化　中国企業、AI技術でリアルタイム撮影

K

Kangxin

USITC Will Investigate State Support And Pricing Practices By Chinese Biotechnology Firms

China Healthcare

BC

Bergeson & Campbell

See more

Healthcare

China Boosts Medical Innovation For Public Health

China will accelerate the development of core medical technologies and innovative drugs targeting common and complex diseases, including cardiovascular conditions...

China Healthcare

AC

AFD China

China On The Move: Key Takeaways From The 2025 NRDL Negotiations And Adjustment

China's role in the global pharmaceutical innovation market is undergoing a substantial shift.

China Healthcare

GT

Greenberg Traurig, LLP

2025年度广告合规洞察：监管新规下的合规之道

自迈入2025年以来，伴随广告行业新业态、新模式、新技术的不断涌现，我国广告监管也迎来了体系化升级，从广告法系列执法指南的出台...

China Media & IT

FP

Fangda Partners

开启直播电商合规新纪元 |《直播电商监督管理办法》重点解读（下）

China Media & IT

FP

Fangda Partners

A Legal Commentary On The Latest Implementing Regulations Of The PRC Drug Administration Law

China Healthcare

FP

Fangda Partners

China Newsletter | Q3 2025/Issue No. 65

GT

Greenberg Traurig, LLP

Navigating China's Health Transformation: Opportunities And Challenges For Multinationals

China Healthcare

AC

Ankura Consulting Group LLC

Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China

China Healthcare

HK

Han Kun Law Offices

China Released Draft Medical Device Law For Comments

China Healthcare

HK

Han Kun Law Offices

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More